Seeking Alpha7d
Atara to cut 50% of workforce amid FDA woes
Atara Biotherapeutics (NASDAQ:ATRA) has announced plans to cut around 50% of its workforce, just a little over a week after it said the FDA had declined to approve its immunotherapy Ebvallo.
Hosted on MSN17d
ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate
Shares of Atara Biotherapeutics ATRA plunged 40.5% on Thursday after the FDA issued a complete response letter (CRL) against the company’s biologics license application (BLA) seeking approval of lead ...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / January 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
Atara Biotherapeutics, Inc. (ATRA) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ('Atara Biotherapeutics, Inc.') ...
Hosted on MSN1mon
Rodman & Renshaw Initiates Coverage of Atara Biotherapeutics (ATRA) with Buy Recommendation
Average portfolio weight of all funds dedicated to ATRA is 0.01%, an increase of 26.88%. Total shares owned by institutions decreased in the last three months by 9.55% to 2,460K shares.